Source Natural Foods & Herbal Supplements Ltd
Incorporated in 1998, Source Natural Foods and Herbal Supplements Ltd deals in ayurvedic products and green energy segment.[1]
- Market Cap ₹ 73.7 Cr.
- Current Price ₹ 114
- High / Low ₹ 170 / 96.6
- Stock P/E 21.0
- Book Value ₹ 40.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 14.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.54 | 10.93 | 15.94 | 10.84 | 12.81 | 13.59 | 24.88 | 21.53 | 19.79 | 27.30 | 44.92 | 70.38 | 79.70 | |
| 5.83 | 9.97 | 14.12 | 9.43 | 11.22 | 11.20 | 20.71 | 17.68 | 16.18 | 22.83 | 40.44 | 64.48 | 73.40 | |
| Operating Profit | 0.71 | 0.96 | 1.82 | 1.41 | 1.59 | 2.39 | 4.17 | 3.85 | 3.61 | 4.47 | 4.48 | 5.90 | 6.30 |
| OPM % | 10.86% | 8.78% | 11.42% | 13.01% | 12.41% | 17.59% | 16.76% | 17.88% | 18.24% | 16.37% | 9.97% | 8.38% | 7.90% |
| 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.33 | 0.49 | 0.01 | -0.04 | 0.08 | 0.06 | 0.23 | |
| Interest | 0.01 | 0.01 | 0.07 | 0.24 | 0.20 | 0.23 | 0.10 | 0.24 | 0.27 | 0.21 | 0.62 | 0.66 | 0.76 |
| Depreciation | 0.54 | 0.49 | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 | 0.42 | 0.62 | 1.04 | 0.36 | 0.38 | 0.72 |
| Profit before tax | 0.16 | 0.47 | 1.41 | 0.83 | 1.05 | 1.84 | 4.03 | 3.68 | 2.73 | 3.18 | 3.58 | 4.92 | 5.05 |
| Tax % | 0.00% | 10.64% | 0.71% | 3.61% | 2.86% | 11.41% | 16.38% | 33.97% | 22.71% | 45.28% | 18.99% | 30.89% | |
| 0.16 | 0.43 | 1.40 | 0.80 | 1.03 | 1.64 | 3.37 | 2.43 | 2.12 | 1.74 | 2.90 | 3.40 | 3.50 | |
| EPS in Rs | 0.26 | 0.67 | 2.17 | 1.24 | 1.60 | 2.55 | 5.24 | 3.78 | 3.29 | 2.70 | 4.51 | 5.28 | 5.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 62.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 23% |
| 3 Years: | 53% |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 0% |
| 3 Years: | 17% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -4% |
| 3 Years: | 9% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 13% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.10 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 |
| Reserves | -0.96 | -0.88 | 0.53 | 1.33 | 2.36 | 3.35 | 6.73 | 9.16 | 11.28 | 13.02 | 15.92 | 19.32 |
| 0.09 | 0.08 | 1.91 | 1.77 | 0.16 | 1.12 | 0.93 | 0.04 | 0.02 | 1.24 | 7.41 | 7.79 | |
| 0.77 | 0.98 | 2.63 | 1.56 | 1.84 | 2.23 | 3.13 | 3.69 | 3.96 | 4.18 | 6.56 | 7.38 | |
| Total Liabilities | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 36.33 | 40.93 |
| 3.66 | 3.31 | 3.53 | 3.58 | 3.57 | 3.31 | 3.88 | 5.00 | 6.56 | 5.52 | 3.93 | 4.16 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.34 | 3.31 | 7.98 | 7.52 | 7.23 | 9.83 | 13.01 | 14.33 | 15.14 | 19.36 | 32.40 | 36.77 | |
| Total Assets | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 36.33 | 40.93 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.38 | 0.38 | -0.69 | 0.11 | 2.64 | -0.36 | 4.46 | -0.70 | 2.51 | 2.69 | 0.07 | -2.49 | |
| -0.40 | -0.16 | -1.95 | 0.14 | -0.31 | -0.71 | -2.09 | 0.07 | 0.06 | 0.29 | -5.33 | -2.36 | |
| 0.11 | 0.01 | 2.06 | -0.42 | -1.60 | 0.32 | 0.32 | -1.20 | -0.53 | 1.19 | 5.40 | -0.17 | |
| Net Cash Flow | 0.08 | 0.23 | -0.58 | -0.18 | 0.74 | -0.74 | 2.69 | -1.83 | 2.04 | 4.18 | 0.13 | -5.01 |
| Free Cash Flow | -0.02 | 0.24 | -1.26 | -0.29 | 2.31 | -0.44 | 3.20 | -1.90 | 2.59 | 2.69 | -0.02 | -3.10 |
| CFO/OP | 54% | 40% | -38% | 8% | 166% | -15% | 107% | -18% | 70% | 60% | 2% | -42% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.84 | 27.72 | 100.52 | 139.06 | 94.88 | 182.37 | 87.88 | 131.22 | 136.67 | 100.41 | 99.46 | 92.68 |
| Inventory Days | 218.30 | 143.24 | 115.92 | 202.88 | 149.49 | 92.38 | 64.09 | 106.83 | 141.55 | 93.59 | 66.20 | 55.94 |
| Days Payable | 108.28 | 81.70 | 84.18 | 36.13 | 46.29 | 58.58 | 22.10 | 57.67 | 78.93 | 60.94 | 35.55 | 35.90 |
| Cash Conversion Cycle | 122.86 | 89.26 | 132.26 | 305.81 | 198.08 | 216.16 | 129.86 | 180.37 | 199.29 | 133.06 | 130.10 | 112.71 |
| Working Capital Days | 57.48 | 53.10 | 74.88 | 124.92 | 112.83 | 155.78 | 68.66 | 163.09 | 156.77 | 98.27 | 54.36 | 77.53 |
| ROCE % | 3.31% | 8.83% | 20.39% | 11.62% | 13.51% | 20.84% | 33.11% | 26.36% | 17.97% | 17.90% | 16.64% | 17.62% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Ayurvedic Medicines Share of Sale of Products % |
|
||||||||
| Number of Permanent Employees count |
|||||||||
| Ojasvita Share of Sale of Products % |
|||||||||
| Veg Capsules & Cookies Share of Sale of Products % |
|||||||||
| Power Consumption KWH |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication for the 31st Annual General Meeting of the Company
-
Corporate Action-Board to consider Dividend
- Book closure from September 24-30, 2026 for the 31st AGM; record date September 23, 2026.
-
Reg. 34 (1) Annual Report.
- 31st AGM on 30 September 2026; annual report FY2025-26 circulated, remote e-voting from 27-29 September.
-
Notice Of 31St Annual General Meeting
- 31st AGM on September 30, 2026 at 11:30 AM; annual report for FY2025-26 circulated.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Board appointed Tejagna K. Katpitia as CFO from 3 Sept 2026; AGM set for 30 Sept 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
SNFHSL is in the business of Ayurvedic Medicines and Foods Supplements segments.
The company is expanding its portfolios in green energy vertical and is also focusing on diversification into wastewater and solid waste
management.